South San Francisco-based Coda Biotherapeutics Inc, a preclinical-stage biopharmaceutical company, has raised a total of $34 million in funding. Versant Ventures was the lead investor in Coda’s latest funding round.
Source: Press Release
South San Francisco-based Coda Biotherapeutics Inc, a preclinical-stage biopharmaceutical company, has raised a total of $34 million in funding. Versant Ventures was the lead investor in Coda’s latest funding round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: